Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHSubmitted by Nathan Reiff. Publication Date: 2/12/2026. 
Article Highlights - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer investors a key window into a firm's pipeline and development progress. Even well-established, stable firms in healthcare can surprise with growth following the release of a new blockbuster drug or medical device, and earnings periods give management a chance to provide context and commentary beyond what investors might glean from FDA approval notices alone. When multiple healthcare companies release earnings on the same day, it can be a busy time for investors who need to sort the notable developments and plan trades accordingly. On Feb. 10, 2025, three major names—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—all reported full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors looking to make informed decisions based on those updates. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance Watch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now U.K.-based pharma giant AstraZeneca closed out 2025 by cementing its position as a leading provider of cancer medicines, which accounted for roughly 44% of product sales in the quarter. Sales of oncology drugs such as Imfinzi and Enhertu grew by as much as 48% year-over-year (YOY), helping drive total revenue up 8.6% to $58.7 billion for the year. After-tax profits rose alongside revenue, climbing to $10.2 billion from $7 billion in the prior-year quarter. The board declared a second interim dividend that was 7 cents higher than last year's. Investors also have near-term catalysts to watch as AstraZeneca advances dozens of drug candidates through trials. Management said 20 Phase 3 readouts are expected in 2026 and reiterated expectations for solid increases in both total revenue and core earnings per share (EPS) for the full year. In the hours after the earnings release, AZN shares rose nearly 3%. Although 10 of 11 analysts rate AZN a Buy or equivalent, some on Wall Street express valuation concerns—the consensus price target of $95.75 implies roughly 51% downside from recent levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Note Margin and EPS Limits Edwards Lifesciences manufactures replacement heart valves, related surgical devices and monitoring systems. Its Q4 2025 results were largely positive: sales grew 13.3% YOY, driven by strong transcatheter aortic valve replacement (TAVR) demand and uptake of the latest SAPIEN valve iteration. However, adjusted EPS missed analyst expectations, and gross profit margin declined 0.8% YOY. Despite some mixed quarterly metrics, Edwards remains confident it can meet its prior 2026 outlook, which targeted sales growth of 8%–10% YOY and EPS of $2.90–$3.05. EW shares jumped above $80—about 4% higher in after-hours trading following the announcement. Roughly two-thirds of analysts rate EW a Buy, and the consensus price target of $96.77 implies about 25% upside from current levels. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Zimmer Biomet, which makes replacement systems and implants for joint and bone disorders, reported EPS of $2.42—$0.04 above consensus—and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of expectations. Strong demand for Zimmer's orthopedic products supported both top- and bottom-line growth, and shares rose more than 3% in the hours after the release. The company is shifting to concentrate more on the U.S. market, which accounts for roughly 60% of its business. Continued utilization gains among insured patients should support demand for Zimmer's products in the near term. Still, Zimmer expects tariffs to remain a headwind that could pressure EPS and revenue in 2026. Management issued conservative guidance in the latest report, forecasting adjusted EPS of $8.30–$8.45 and free cash flow improvement of 8%–10%. Before the earnings release, analysts were mixed on Zimmer, assigning an overall Hold rating even though the consensus implies about 15% upside.
| 
